AN0025
Phase 1Active 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Cancer
Conditions
Esophageal Cancer
Trial Timeline
Jan 18, 2022 โ Dec 1, 2025
NCT ID
NCT05191667About AN0025
AN0025 is a phase 1 stage product being developed by Adlai Nortye for Esophageal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05191667. Target conditions include Esophageal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05358691 | Phase 1 | Withdrawn |
| NCT05191667 | Phase 1 | Active |
Competing Products
20 competing products in Esophageal Cancer